Dr. Ayal Hendel, of Bar-Ilan University’s Mina and Everard Goodman Faculty of Life Sciences and Institute of Nanotechnology and Advanced Materials, is part of a European consortium that has been awarded a grant of more than €6 million to assess the efficacy and safety of genome editing approaches for sickle cell disease. Read More.
